CP
TSHA icon

Camelot Portfolios’s Taysha Gene Therapies TSHA Stock Holding History

Camelot Portfolios’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,000
Closed -$15.3K – 220
2025
Q1 		$15.3K Buy
+11,000
New +$18.4K 0.01% 207
2024
Q3 		– Sell
-11,000
Closed -$24.6K – 519
2024
Q2 		$24.6K Buy
+11,000
New +$32K 0.01% 353
2024
Q1 		– Sell
-11,000
Closed -$19.5K – 203
2023
Q4 		$19.5K Buy
+11,000
New +$21.9K 0.01% 209
2023
Q3 		– Sell
-11,000
Closed -$7.27K – 194
2023
Q2 		$7.27K Hold
11,000
– – ﹤0.01% 195
2023
Q1 		$8.77K Buy
+11,000
New +$14.2K 0.01% 181

Other funds holding TSHA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Camelot Portfolios's TSHA Position: Q2 2025 in Review

Camelot Portfolios sold out of Taysha Gene Therapies (TSHA) in Q2 2025, closing a stake of 11,000 shares — an estimated $15.3K sold.

Camelot Portfolios first reported a position in TSHA in Q1 2023 and held it in 5 quarters. The position peaked at $24.6K in Q2 2024. 150 funds tracked by Wall St. Rank hold TSHA as of Q2 2025.

  • Camelot Portfolios reported no remaining Taysha Gene Therapies position as of Q2 2025 after selling out during the quarter.
  • Camelot Portfolios sold 11,000 Taysha Gene Therapies shares in Q2 2025, an estimated $15.3K.
  • Camelot Portfolios first reported a position in Taysha Gene Therapies in Q1 2023 and held it in 5 quarters.
  • Camelot Portfolios's Taysha Gene Therapies position peaked at $24.6K in Q2 2024.
  • 150 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2025.

Based on Camelot Portfolios's 13F filing for Q2 2025, filed 17 Jul 2025.